CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD19 CAR-T 细胞治疗急性期的多发性溃疡伴小肠穿孔，可能与应用托珠单抗相关
英文原题：Multiple Ulcers with Perforations of the Small Intestine in the Acute Phase of CD19 Chimeric Antigen Receptor T-cell Therapy Possibly Associated with Tocilizumab Administration.
查看英文原题
Multiple Ulcers with Perforations of the Small Intestine in the Acute Phase of CD19 Chimeric Antigen Receptor T-cell Therapy Possibly Associated with Tocilizumab Administration.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD19嵌合抗原受体（CAR）T细胞治疗与可能危及生命的免疫毒性相关。我们在此报告一例81岁女性，在因复发难治性滤泡性淋巴瘤（无胃肠道受累）接受tisagenlecleucel输注后8天，发生小肠多处穿孔。切除小肠的病理检查显示，切除后形成的多发溃疡，但无淋巴瘤累及。基于这些发现，用于细胞因子释放综合征的tocilizumab被认为与这些病变相关。本例揭示了CAR-T 细胞治疗一种此前未描述的但严重的后遗症，呼吁相关人员对胃肠道症状保持警惕。
展开英文摘要原文
CD19 chimeric antigen receptor (CAR) T-cell therapy is associated with potentially life-threatening immunological toxicities.
We herein report an 81-year-old woman who experienced multiple perforations in the small intestine 8 days after tisagenlecleucel infusion for relapsed and refractory follicular lymphoma with no gastrointestinal involvement. A pathological examination of the resected small intestine revealed multiple ulcers that formed after resection but without lymphoma involvement.
Based on these findings, tocilizumab used for cytokine release syndrome was considered to be associated with these lesions. This case illustrates a previously undescribed but serious sequela of CAR T-cell therapy, calling for relevant personnel to be vigilant about gastrointestinal symptoms.
论文信息
- 作者
- Masuda Y、Honda A、Yasunaga Y、Kurokawa M
- 单位
- Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan.Japan
- 文献类型
- 病例报告
- 期刊
- Internal medicine (Tokyo, Japan)2025
- 原文标识
- PubMed 39894508 · DOI 10.2169/internalmedicine.3815-24
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →